Ligand Pharma (LGND) PT Lowered to $135 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Ligand Pharma (LGND) PT Lowered to $150 at Barclays
October 25, 2022 5:54 AM EDTBarclays analyst Balaji Prasad lowered the price target on Ligand Pharma (NASDAQ: LGND) to $150.00 (from $157.00) while maintaining a Overweight rating.... More
OmniAb Business Combination Approved by APAC Shareholders (AHPA)
October 24, 2022 5:04 PM EDTLigand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the business combination (Business Combination) of Avista Public Acquisition Corp. II (APAC) (NASDAQ: AHPA) and OmniAb, Inc. (OmniAb), was approved by APAC shareholders in a vote held this morning, with 96% of the shares represented in person, virtually or by proxy voting in favor of the combination. Based on actual redemptions and estimated expenses, OmniAb expects to have approximately $95 million of net cash upon the closing of the Business Combination (Closing). Prior to the Business Combination, APAC will domesticate in... More
